KAHR Medical is a biopharmaceutical company developing an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications.
KAHR Medical was founded in 2005 and is headquartered in Jerusalem, Jerusalem District, Israel.
KAHR’s proprietary technology, known as DSP (Dual Signaling Proteins), enables the construction of targeted biological drugs with two functional ends, which can simultaneously block and/or activate two reinforcing biological signals resulting in a synergistic outcome.
KAHR’s new DSP platform emerged following years of research and development of TNF-superfamily based drug candidates. This platform represents a new generation of ultra-active immunotherapeutic biological drugs rationally designed for the treatment of multiple cancer indications.
KAHR Medical is backed by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings (HBL), Pavilion Capital, Mirae Asset Venture Investment. The company raised $18M in a latest financing on Feb 25, 2020. This brings KAHR's total funding to $40M to date.